BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology ...

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for ... of market stability and pipeline progress. It is conceivable that the company’s share ...

Clinical Progress and Outlook ... attributable to higher expense associated with clinical trials and one-time employee termination benefits primarily offset by lower preclinical research expense ...

Named Ron Weitzman, M.D., F.A.C.P., as part-time Chief Medical Officer. Cash Position: Cash, cash equivalents and marketable securities were $41.3 million as of December 31, 2024, as compared to $ ...

While inflation remains above the Fed’s 2% target, core consumer prices have decelerated significantly over the past year, signaling progress in ... Dupixent, Libtayo, Kevzara, and others.

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...

Regulatory progress continues ... Key products like EYLEA, Libtayo, and Dupixent propelled the company’s growth. Dupixent continues to be a major success, treating over a million patients ...